GPC Biotech

GPC Biotech AG
legal form	AG
Seat	Martinsried , Germany
management	Bernd R. Seizinger (CEO)
Number of employees	114 (2008)
sales	EUR 23 million (2006)
Branch	biotechnology

In Neuenheimer Feld 515 - registered office in Heidelberg

GPC Biotech was a biotechnology company engaged in the research and development of anti- cancer drugs . On November 5, 2009, the company was taken over by Agennix AG . On May 23, 2013, Agennix announced the liquidation of the company.

history

This article or the following section is not adequately provided with supporting documents ( e.g. individual evidence ). Information without sufficient evidence could be removed soon. Please help Wikipedia by researching the information and including good evidence.

GPC Biotech was listed on the German stock exchange in Frankfurt am Main, since March 2003 in the TecDAX 30 . On December 27, 2007, the shares of GPC Biotech were removed from the TecDax . In the USA, the share was listed in the NASDAQ Health Care Index .

At the end of November 2005, the company received the “€ uro Corporate Governance Quality Award” from the financial magazine € uro for the second time as a company with the best corporate governance (company transparency) in the TecDAX. In the overall evaluation of all criteria, it was ranked 9th out of 100 companies evaluated.

In 2005, the company partnered with Pharmion Corporation in drug development, marketing and sales for Europe and several other countries ; an alliance was also intended for Japan.

Among other things , GPC Biotech developed satraplatin , an oral chemotherapy agent (especially in combination with products from other companies) for prostate cancer that is already hormone-resistant . GPC Biotech wanted to develop the US market for satraplatin on its own. The US development and licensing partner since December 19, 2005 was Spectrum Pharmaceuticals . Arbitration proceedings were pending with this company in 2007.

Satraplatin approval application for Europe was planned for 2007. Following a negative FDA evaluation of the drug , the stock fell 34 percent on July 20, 2007, and plunged over 60% on October 31, 2007 because the named drug, satraplatin, missed key research targets.

The GPC Biotech AG merged in 2009 with the American company Agennix.

structure

The company's headquarters were in Martinsried / Planegg (56 employees) near Munich. The US subsidiary GPC Biotech Inc. was located in Waltham / Boston (Massachusetts, closed at the end of 2007) and Princeton (New Jersey, 58 employees). The CEO of GPC Biotech has been Bernd R. Seizinger since 1998, and Jürgen Drews was the Chairman of the Supervisory Board .

The family of the SAP founder Dietmar Hopp held about 14% of the shares (via intermediate companies). At the end of September 2006, Altana , the second largest shareholder until then, sold the 7.1% stake in GPC Biotech to Goldman Sachs , which it had held since 2001, after divesting its pharmaceuticals division .

Web links

• Sebastian Ramspeck, Michaela Schießl: "That is not a death sentence" . In: Der Spiegel . No. 31 , 2007, p. 70 f . ( online - July 30, 2007 ).
• historical fragments from www.gpc-biotech.com ( Memento from May 20, 2009 in the Internet Archive )

Individual evidence

1. ↑ Agennix is ​​being liquidated on transkript.de ( Memento from May 12, 2014 in the Internet Archive ), accessed on August 21, 2013.

Coordinates: 49 ° 25 ′ 16.7 "  N , 8 ° 40 ′ 28.2"  E